BACKGROUND: Expression of class ΙΙΙ β-tubulin (βΙΙΙ-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βΙΙΙ-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. PATIENTS AND METHODS: We determined βΙΙΙ-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βΙΙΙ-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. RESULTS: High βΙΙΙ-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P = .003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER(-) tumors treated with neoadjuvant chemotherapy, high βΙΙΙ-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P = .021). CONCLUSION: This study reveals differential βΙΙΙ-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βΙΙΙ-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER(-) breast cancer, which has not been previously reported. These data provide a strong rationale for considering βΙΙΙ-tubulin status and further validation of this marker in a large study.
BACKGROUND: Expression of class ΙΙΙ β-tubulin (βΙΙΙ-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several humanmalignancies including breast cancer. However its predictive value in a neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether βΙΙΙ-tubulin expression in breast cancer correlated with pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy. PATIENTS AND METHODS: We determined βΙΙΙ-tubulin expression in 85 breast cancers, including 41 localized breast cancers treated with primary surgery and 44 treated with neoadjuvant chemotherapy before surgery. βΙΙΙ-tubulin expression was evaluated by immunohistochemical methods and was correlated with pathologic characteristics and response to neoadjuvant chemotherapy using residual cancer burden (RCB) score. RESULTS: High βΙΙΙ-tubulin expression was significantly associated with poorly differentiated high-grade breast cancers (P = .003) but not with tumor size, estrogen receptor (ER) status, or human epidermal growth factor receptor 2 (HER2)/neu overexpression. In ER(-) tumors treated with neoadjuvant chemotherapy, high βΙΙΙ-tubulin expression was associated with a significantly greater likelihood of achieving a good pathologic response to chemotherapy as reflected by lower RCB scores (P = .021). CONCLUSION: This study reveals differential βΙΙΙ-tubulin expression in breast cancers of different histologic grades, hormone receptors, and HER2/neu status. It also suggests a potential role for βΙΙΙ-tubulin as a predictive biomarker for response in neoadjuvant chemotherapy for ER(-) breast cancer, which has not been previously reported. These data provide a strong rationale for considering βΙΙΙ-tubulin status and further validation of this marker in a large study.
Authors: A Paradiso; A Mangia; A Chiriatti; S Tommasi; A Zito; A Latorre; F Schittulli; V Lorusso Journal: Ann Oncol Date: 2005-05 Impact factor: 32.976
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: Chantal Bernard-Marty; Isabelle Treilleux; Charles Dumontet; Fatima Cardoso; Arlette Fellous; David Gancberg; Marie Christine Bissery; Marianne Paesmans; Denis Larsimont; Martine J Piccart; Angelo Di Leo Journal: Clin Breast Cancer Date: 2002-12 Impact factor: 3.225
Authors: Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming-Sound Tsao; Frances A Shepherd; Tony Reiman Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee Journal: Invest New Drugs Date: 2015-12-21 Impact factor: 3.850
Authors: Hee Young Na; Mira Park; Young A Kim; Jae Kyung Won; Young Joo Park; Sun Ah Shin; Sejoon Lee; Sohee Oh; Ji Eun Kim Journal: J Clin Med Date: 2020-11-26 Impact factor: 4.241
Authors: Patrick Lebok; Melike Öztürk; Uwe Heilenkötter; Fritz Jaenicke; Volkmar Müller; Peter Paluchowski; Stefan Geist; Christian Wilke; Eicke Burandt; Annette Lebeau; Waldemar Wilczak; Till Krech; Ronald Simon; Guido Sauter; Alexander Quaas Journal: Oncol Lett Date: 2016-02-09 Impact factor: 2.967